Loading organizations...
OPER provides a mobile platform that integrates food ordering, payment processing, and a comprehensive rewards program for restaurant diners. The company’s core product allows users to conveniently place orders for carryout and delivery directly from their mobile devices while simultaneously earning and redeeming loyalty points. This unified system aims to streamline the customer experience, enabling seamless transactions and fostering greater engagement through automated rewards.
The company was founded in March 2015 by David Laiderman, an entrepreneur with a deep background in restaurant technology. Laiderman began developing solutions for the restaurant industry in the early 2000s, an experience that included co-founding Lionmenus.com, which was later acquired. His accumulated expertise and understanding of the sector's needs informed the development of OPER, addressing operational challenges and enhancing customer loyalty.
OPER serves both restaurant operators seeking to optimize their digital presence and diners desiring a more rewarding and efficient way to interact with their favorite establishments. Its vision centers on transforming the dining experience by making it more convenient and beneficial for consumers, while simultaneously equipping restaurants with essential tools to cultivate customer loyalty and drive incremental revenue in an increasingly digital landscape.
Oper has raised $11.6M across 2 funding rounds.
Oper has raised $11.6M in total across 2 funding rounds.
# High-Level Overview
OPER Technology Limited is a biotechnology company focused on developing innovative nanomaterial-based personalized medicine technologies[3][4]. The company specializes in creating solutions for precision medicine, regenerative medicine, and personalized therapy, with particular emphasis on individualized stem cell therapies[5][6].
Based in Hong Kong, OPER Technology operates as a biotechnology research firm with approximately $4 million in revenue and a small team[2]. The company's core mission centers on making advanced personalized medical treatments more accessible and affordable through its proprietary nano-medicine platform[3]. Rather than serving as a traditional investment firm, OPER Technology functions as a portfolio company itself—a specialized biotech developer addressing the growing demand for tailored medical interventions.
# Core Differentiators
OPER Technology's competitive advantages center on its technological foundation:
# Role in the Broader Tech Landscape
OPER Technology operates within the rapidly expanding precision medicine and personalized therapy sector. This space benefits from converging trends: advances in nanotechnology, growing understanding of individual genetic variation, and increasing healthcare costs driving demand for more targeted, efficient treatments. The company's focus on making personalized medicine "inexpensive" addresses a critical market need—precision therapies have historically been prohibitively expensive, limiting accessibility[3].
The nanomaterial-based approach represents a meaningful technical direction within biotech, as nano-scale interventions can potentially improve drug delivery, reduce side effects, and enable more precise therapeutic targeting. OPER Technology's emphasis on stem cell therapies positions it within regenerative medicine, another high-growth segment expected to reshape treatment paradigms.
# Quick Take & Future Outlook
OPER Technology represents a specialized biotech player betting on the convergence of nanotechnology and personalized medicine. As healthcare systems worldwide grapple with cost pressures and the promise of genomic medicine remains largely unfulfilled at scale, companies developing accessible personalized treatments occupy a strategically important position.
The company's relatively modest current scale ($4 million revenue) suggests it remains in early commercialization stages. Success will depend on translating its nano-medicine platform from development into clinical validation and regulatory approval—a lengthy, capital-intensive process typical in biotech. If the company can demonstrate clinical efficacy while maintaining cost advantages, it could address a genuine market gap where precision medicine meets affordability.
Oper has raised $11.6M across 2 funding rounds. Most recently, it raised $11.0M Series A in July 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2022 | $11M Series A | Bessemer Venture Partners, TIM Wanders, ABN AMRO Ventures | Zigg Capital, Pitchdrive, Techstars, Verve Ventures | Announced |
| Jul 1, 2020 | $570K Seed | — | Pario Ventures, Pitchdrive, WIM Derkinderen, Barclays | Announced |
Oper has raised $11.6M in total across 2 funding rounds.
Oper's investors include Bessemer Venture Partners, Tim Wanders, ABN AMRO Ventures, Zigg Capital, Pitchdrive, Techstars, Verve Ventures, Pario Ventures, Wim Derkinderen, Barclays.
